aTyr Pharma

📍 San Diego, United States👥 77 employees💰 Last funded Jul 2019
Biotechnology Research🌐 atyrpharma.com
Website LinkedIn
aTyr Pharma (Nasdaq: LIFE) is a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological pathways. aTyr’s research and development efforts are concentrated on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. aTyr has built a global intellectual property estate directed to a potential pipeline of protein compositions derived from 20 tRNA synthetase genes and their extracellular targets. aTyr’s primary focus is efzofitimod (ATYR1923), a clinical-stage product candidate which binds to the neuropilin-2 receptor and is designed to down-regulate immune engagement in severe inflammatory lung diseases. For more information, please visit http://www.atyrpharma.com. The Company was founded by Professors Paul Schimmel, Ph.D., and Xiang-Lei Yang, Ph.D., two leading aminoacyl tRNA synthetase scientists at The Scripps Research Institute.
2
Total investors
0
Early stage
0
Mid stage
0
Late stage
—
Founded

Investors

2 investors
All
Early stage
Mid stage
Late stage
Investor geography1 country
United States
1
Frequently asked questions
Who invested in aTyr Pharma?
aTyr Pharma has 2 investors on record on gritt.io.
When did aTyr Pharma last raise funding?
The most recent investment in aTyr Pharma recorded on gritt.io was in July 2019.
What industry is aTyr Pharma in?
aTyr Pharma operates in Biotechnology Research. Find similar Biotechnology Research investors on gritt.io.
Where is aTyr Pharma based?
aTyr Pharma is headquartered in San Diego, United States.